Pfizer COVID-19 Booster Is 95.6% Effective Against Symptomatic Cases, Clinical Trial Suggests

The New York Times (10/21, Rabin) reports booster shots “in adults who received the Pfizer-BioNTech vaccine were highly effective at preventing symptomatic COVID-19 breakthrough infections.” Pfizer “said that out of more than 5,000 Pfizer-BioNTech vaccine...